about
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsGene essentiality and synthetic lethality in haploid human cellsArtemisinins Target GABAA Receptor Signaling and Impair α Cell IdentityA cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.Isobar(PTM): a software tool for the quantitative analysis of post-translationally modified proteinsMultiple and sequential data acquisition method: an improved method for fragmentation and detection of cross-linked peptides on a hybrid linear trap quadrupole Orbitrap Velos mass spectrometer.Detecting the impact of sequencing errors on SAGE data.High-performance peptide identification by tandem mass spectrometry allows reliable automatic data processing in proteomics.Assessing peptide de novo sequencing algorithms performance on large and diverse data sets.InSilicoSpectro: an open-source proteomics library.MASPECTRAS 2: An integration and analysis platform for proteomic data.A chemical and phosphoproteomic characterization of dasatinib action in lung cancerTOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens.General statistical modeling of data from protein relative expression isobaric tags.A time-resolved molecular map of the macrophage response to VSV infectionFunctional dissection of the TBK1 molecular networkA miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsiesA reversible gene trap collection empowers haploid genetics in human cells.Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomicsUsing iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer.Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2.Targeting a cell state common to triple-negative breast cancersA chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProteome-wide drug and metabolite interaction mapping by thermal-stability profiling.Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels.Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative DamageA combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.Systems biology analysis of protein-drug interactions.Proteomic analysis of human cataract aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ®-labelled specimens.A Surface Biotinylation Strategy for Reproducible Plasma Membrane Protein Purification and Tracking of Genetic and Drug-Induced Alterations.NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.Affinity purification strategies for proteomic analysis of transcription factor complexes.A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.Building and exploring an integrated human kinase network: global organization and medical entry points.Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions.The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.The RNA-binding protein HuR/ELAVL1 regulates IFN-β mRNA abundance and the type I IFN response.
P50
Q24339394-CB19969F-6DD5-4B96-810A-0B37D62A1757Q28771731-E2A54186-CB07-4738-BEAC-B80F525218ABQ30365127-F42241AA-B94E-4F71-8ED0-9D0D7F9565ECQ30396736-37D255B9-5EF7-4FD7-A9ED-87AECD47589CQ30543933-AF674A99-1896-4E47-AE39-4DFE936C125DQ30585255-B355F586-DDFE-473B-BF35-FD731EFF2892Q30661944-F0B3DC75-4DB7-4389-933D-C202BD61B5D5Q30940131-643E1884-7E30-484D-993C-C14D5288A42BQ31120970-4F2C3388-6630-44C0-81F5-37C7021EEAC5Q33235251-6B2B6AF7-E170-47A5-855C-7DAEC799A7A4Q33573781-C925DB5F-EC82-4FCE-885B-EFDB7594EAEAQ33742159-5719C91B-0471-44B8-BF89-2011154F74F1Q33828463-E9EA967F-7646-4AF9-9F37-30F2A003623FQ33883919-177E3153-93DC-44C0-ADB0-2D6327DDC79DQ33917851-F03BBB51-D106-407E-AA78-5017BEA1E0B3Q34023215-35507BAE-C8D3-4E86-956C-5E3B8A70F8DBQ34024820-444A429A-C696-46D6-8F80-1ABB9EBDA29AQ34380363-C1DF8271-C228-4A54-ABAC-68266860F91DQ34458274-03A41033-6F44-4756-B4D6-37A3E0AE23ADQ34474427-D8472FD2-C6E3-43F8-ACB6-1FD27985D69AQ34677647-3D5FAFE1-BC31-4E55-AABE-FF4C87A8F421Q35136778-BD050E7B-D9C5-40DC-9083-C3FFFC48D2B4Q35174128-F7EC495E-1711-4C9B-9E85-465D8F0B8197Q35837764-EEA79062-4A30-467C-8884-59905CA47CFEQ35925610-23C2B1E3-3D5B-486E-986E-FC72FCBADC07Q36238589-90E33D80-A4DB-4158-8C45-B3E9F53089EBQ36304917-529D8D58-4E74-47E0-AEAA-B3DE4EF4F7C1Q36315988-3399FCCE-15D5-45F8-A230-3DA92C3E8693Q36377541-77DF4444-E921-4930-99AB-24D12BC4AFB0Q37972867-496D01EB-3BEB-4A5F-8A29-38A4A4C5E40BQ38504739-BF93EE64-A847-4235-AA63-402B3AAC015DQ38809436-A80CAD45-562F-405A-97EA-5C95BA9085D1Q38952574-8BAABC95-6D2E-4535-80B3-1917BA0CAA6BQ39111468-9889DC09-E9E7-41F3-930E-EFDAA2B31200Q39144779-B3CBBB0A-3501-40F9-9ECD-7F6887C73124Q39215261-04848FF9-F643-4E2C-8C0D-6B69B92AB4FFQ39268913-040244A7-E57D-4803-A12C-0B9C3F96CA28Q40474101-6DD59C5B-EE43-43E8-B8DE-CD8156B5F90EQ41129829-7B50B2BA-9389-492D-82CE-5B67E06CBBB3Q41441442-CE1D845E-8996-4A44-BF0E-D0EBEC19AB91
P50
description
researcher ORCID ID=0000-0003-2466-4824
@en
wetenschapper
@nl
name
Jacques Colinge
@en
Jacques Colinge
@nl
type
label
Jacques Colinge
@en
Jacques Colinge
@nl
prefLabel
Jacques Colinge
@en
Jacques Colinge
@nl
P106
P21
P31
P496
0000-0003-2466-4824